EUCTR2008-007978-38-CZ进行中（未招募）不适用
A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for Up to 13 Weeks in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) - IN-STEP (Indantadol - Safety Tolerability and Efficacy in Pain
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Signed written informed consent
- •2)Male or female 18 – 75 years of age
- •3)Diagnosis of diabetes mellitus (Type I or II)
- •4)No change in diabetes medications within 4 weeks before screening
- •5)Daily pain attributed to diabetic neuropathy present for at least 6 months immediately prior to study entry
- •6)Presents with pain due to bilateral peripheral neuropathy caused by Type I or Type II diabetes mellitus. Pain must have begun in the feet, with relatively symmetrical onset. The diagnosis must be confirmed by a score of at least 2 on Section B (Physical Assessment) of the Michigan Neuropathy Screening Instrument (MNSI)
- •7)Judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol
- •8)Females should be of non child-bearing potential (i.e., surgically sterilized or at least 1 year post-menopause). Male subjects who are sexually active with a female partner of child bearing potential must agree to use a barrier method of contraception (eg condom, diaphragm or cervical cap in the female partner) for the duration of the study (until the follow up visit).
- •Final Inclusion Criteria
- •Before patients are randomised to double-blind study drug treatment, the following additional inclusion criteria fulfillment must be established at the baseline visit:
- •9)A mean average pain intensity of at least 4, but less than or equal to 9, on an 11 point Likert NPRS recorded twice daily (in the morning and evening) during the two week placebo run-in before randomisation (baseline); however, any patient who experiences a >30% decrease in the mean pain score compared to Day -16 (Screening) score, during placebo run-in will be excluded, regardless of whether their final score is greater than or equal to 4
- •10)Full completion of the daily diaries for at least 11 of the placebo run-in days.
- •11)Compliance in taking study medication twice daily for at least 11 of the placebo run-in days
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1)Any clinically significant neurologic disorders (with the exception of diabetic peripheral neuropathic pain)
- •2)Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient’s ability to participate in the study
- •3)Prior renal transplant, current renal dialysis
- •4)Pernicious anemia
- •5)Untreated hypothyroidism
- •6)Amputations or persistent ulceration due to diabetes mellitus
- •7)Any cardiovascular condition that would be a contraindication to the use of sympathomimetic amines (e.g., active angina)
- •8)Uncontrolled hypertension (i.e., >140/90 mm Hg despite adequate medical therapy)
- •9)Known or at high risk of human immunodeficiency virus (HIV) infection
- •10)Any anticipated need for surgery during the study
- •11)Increased risk of seizures (defined as a history of seizure disorder (including alcoholic seizures), family history of seizures and history of head trauma that resulted in loss of consciousness or concussion).
- •12)Any malignancy in the past 2 years (with the exception of basal cell carcinoma)
- •13)Pain that cannot be clearly differentiated from, or conditions that interfere with, the assessment of diabetic neuropathic pain. Examples of painful conditions that could be confused with diabetic neuropathic pain include: peripheral vascular disease (ischemic pain); neurological disorders unrelated to diabetic neuropathy (e.g., phantom limb pain from amputation); skin condition in the area of the neuropathy that could alter sensation (e.g., plantar ulcer); other painful conditions (e.g., arthritis)
- •14)Use of anticonvulsants, antidepressants (particularly MAO inhibitors), or prescription membrane-stabilizing agents, including topical therapies. Patients currently taking drugs in these classes may have them discontinued prior to entry into the placebo run-in period. Selective serotonin reuptake inhibitors should be discontinued at least 4 weeks prior to the run-in period; all other prohibited medications should be discontinued 2 weeks prior to run-in.
- •15)Use of opioids, especially meperidine (pethidine)
- •16)History of substance abuse or dependence within the past year, excluding nicotine and caffeine
- •17)Frequent and/or severe allergic reactions with multiple medications
- •18)Historical exposure to drugs known to cause neuropathy (for example, vincristine), or a history of a medical condition, including pernicious anemia and hypothyroidism, that could have been responsible for neuropathy
- •19)Patients taking excluded medications that cannot be stopped at the baseline visit
- •20)Participation in any clinical trial within 30 days before screening
- •Final Exclusion Criteria
- •Before patients are randomised to double-blind study drug treatment, the following additional exclusion criteria fulfillment must be established at the baseline visit:
- •21)A score of 20 or more on the Beck Depression Inventory-II
- •22)Glycosylated haemoglobin (HbA1c) >11.0%
- •23)Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance <60 mL/min
- •24)Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert’s syndrome) and/or alanine transaminase (ALT) >1.5 times upper limit of normal reference ranges (after adjustment for age)
- •25)Any clinically significant abnormal laboratory test result(s) that would jeopardize the patient’s capacity to undergo investigative study treatment
研究者
相似试验
进行中（未招募）
1 期
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)Resected Squamous Cell Carcinoma of the Head and NeckMedDRA version: 8.1 Level: LLT Classification code 10041823 Term: Squamous cell carcinomaEUCTR2006-001623-18-GBGlaxoSmithKline Research & Development Limited688
进行中（未招募）
1 期
Phase II Study to evaluate Olaparib with Abiraterone in treating metastatic castration resistant prostate cancermetastatic castrate-resistant prostate cancerMedDRA version: 21.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003520-37-NLAstraZeneca AB158
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)EUCTR2006-001623-18-EEGlaxoSmithKline Research & Development Limited680
进行中（未招募）
1 期
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures. - ELEVATEThrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive ProceduresMedDRA version: 9.1Level: LLTClassification code 10008953Term: Chronic liver diseaseEUCTR2007-005851-40-FRGlaxoSmithKline Research and Development Ltd
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)EUCTR2006-001623-18-PTGlaxoSmithKline Research & Development Limited680